Nexalin Therapy as a Viable Adjunctive Treatment for Substance Use Disorders

NAActive, not recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 11, 2018

Primary Completion Date

April 30, 2019

Study Completion Date

November 30, 2019

Conditions
DepressionAnxietyInsomniaSubstance Abuse
Interventions
DEVICE

TES Treatment

Device: Nexalin Based Trans-Cranial Electrical Stimulation The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current. Other Name: TES

DEVICE

TES-SHAM Treatment

Device: Nexalin Based Trans-Cranial Electrical Stimulation The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current. Other Name: TES

Trial Locations (1)

08502

Carrier Clinic, Belle Mead

All Listed Sponsors
collaborator

Carrier Clinic

OTHER

lead

University of Arizona

OTHER

NCT03540745 - Nexalin Therapy as a Viable Adjunctive Treatment for Substance Use Disorders | Biotech Hunter | Biotech Hunter